결절성 양진 치료제 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the prurigo nodularis therapeutics market size is expected to increase from USD 2.09 billion in 2025 to USD 2.16 billion in 2026 and reach USD 2.64 billion by 2031, growing at a CAGR of 4.08% over 2026-2031.

This report is Segmented by Drug Class (Corticosteroids, Antihistamines, Anticonvulsants, Biologics, Others), Route of Administration (Topical, Oral, Injectable), End-User Setting (Hospitals, Specialty Clinics, Home-Care), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). Market Forecasts are in Value (USD).

Global Prurigo Nodularis Therapeutics Market Trends and Insights

Regulatory Tailwinds for Orphan & Rare-Disease Biologics (US & EU)

Accelerated pathways and rare-disease incentives are compressing time from submission to launch for therapies that address severe pruritus and refractory lesions. Nemolizumab's U.S. priority review approval in February 2024 showcased how priority review can move efficacious biologics to market on faster timelines for adult patients who had limited systemic options. U.K. authorization in February 2025 reinforced the trend of cross-border regulatory convergence that now supports earlier clinician familiarity and coordinated payer reviews. These precedents clarify approvability criteria rooted in clinically meaningful itch reduction and physician assessment scales, which benefit agents that target upstream cytokine signaling. Sponsors also gain economic benefits through fee waivers and exclusivity windows, which improve the risk-adjusted return profiles of late-stage assets in the prurigo nodularis therapeutics market. As more dossiers leverage consistent endpoints and robust patient-reported outcomes, submission quality rises, and review cycles become more predictable for follow-on mechanisms.

Rapid Expansion of Tele-Dermatology & E-Pharmacy Fulfillment

Synchronous and asynchronous teledermatology is expanding specialist reach by triaging routine follow-ups and image-based consultations outside crowded clinics. Peer-reviewed work demonstrates that store-and-forward workflows can lower in-person demand and modestly reduce acute care visits in underserved communities, which preserves capacity for systemic initiation and monitoring. Specialty pharmacy networks supply home delivery of prefilled injectors and align with virtual education models, which improve adherence and support stable persistence for injectable biologics. Autoinjector formats also reduce per-dose administration costs compared with clinic-based injections, which aligns payer incentives with home-care use in the prurigo nodularis therapeutics market. As clinics implement tele-triage and remote documentation for adherence, dermatology teams can allocate in-person time to complex flares and comorbidities. This integrated model enables consistent follow-up for patients who live far from specialist centers, which stabilizes chronic-care workflows around targeted biologics and late-stage small molecules.

High Biologic Therapy Cost & Payer Utilization Controls

Biologic list prices and site-of-care costs continue to draw intense scrutiny, which sustains step-therapy and prior authorization requirements that delay treatment starts. Medicare Part B reimbursement mechanics use average sales price formulas that adjust with a lag, which can pressure provider economics for buy-and-bill launches. Federal analyses and policy discussions on biosimilars aim to reduce spending while maintaining access, which creates uncertainty for innovators that rely on stable margins to fund follow-on research. Payer controls also vary across plan types, which means that the same patient profile can experience different access pathways depending on coverage. These factors can slow uptake novel biologics and shift more care to home-based self-administration, where payers seek lower total costs. The prurigo nodularis therapeutics market continues to navigate these constraints by expanding patient support programs and by aligning delivery models to plan preferences.

Other drivers and restraints analyzed in the detailed report include:

1. IL-31 / OSM Pathway Breakthroughs Accelerating Novel MoA Pipeline
2. Rise of Patient-Advocacy Rare-Disease Registries Speeding Clinical Trial Enrollment
3. Heterogeneous Disease Phenotypes Complicate Endpoint Standardization in Trials

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Biologics captured 45.34% of the prurigo nodularis therapeutics market in 2025, and the prurigo nodularis therapeutics market size for biologics is projected to expand at a 7.49% CAGR through 2031. Targeting upstream cytokines has improved itch control and disease management compared with symptomatic regimens, which is why dermatology clinics are transitioning moderate-to-severe patients to IL-31RA and IL-4/IL-13 blockade once initial measures fall short. Nemolizumab's approval brought a distinct IL-31 mechanism into routine practice and created clear sequencing options alongside an established IL-4/IL-13 biologic. Topical corticosteroids and other local therapies remain a first step in mild presentations, but they function mainly as adjuncts once systemic therapy begins for refractory itch and persistent nodules. Antihistamines have limited utility because non-histaminergic circuits drive itch signaling in this disease, which keeps them peripheral to control strategies for severe cases.

Small-molecule programs are advancing to offer alternatives for patients who prefer oral routes or who face injection barriers. Oral agents that modulate JAK-STAT signaling are designed to intercept downstream pathways activated by multiple cytokines, which could broaden responsiveness across phenotypes. Published reviews highlight that dose optimization and safety monitoring are central to long-term use as these agents mature through late-stage trials. As evidence accumulates, clinicians are considering combination strategies that pair systemic agents with targeted topical care to enhance clearance and lower flare risk. The prurigo nodularis therapeutics market is therefore organizing around a biologics-led core with oral entrants providing greater choice on delivery, which supports adherence patterns that suit patient preferences and payer policies.

Complete Report Scope:

• By Drug Class
  • Topical Corticosteroids
  • Capsaicin Cream
  • Antihistamines
  • Anticonvulsants
  • Antidepressants
  • NK-1 Receptor Antagonists
  • Biologics
  • Opiate Receptor Modulators
  • Others (Phototherapy, Cryotherapy, etc.)
• By Route of Administration
  • Topical
  • Oral
  • Subcutaneous / Intramuscular Injection
• By End-User Setting
  • Hospitals
  • Specialty Dermatology Clinics
  • Home-care / Self-administration
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 42.11% of the prurigo nodularis therapeutics market in 2025, reflecting mature specialty pharmacy systems and broad clinician familiarity with targeted immunology agents. U.S. coverage for nemolizumab advanced rapidly, with first-line biologic access extending to a substantial share of commercially insured lives soon after launch, which reinforced early momentum in the prurigo nodularis therapeutics market. Canada contributes a smaller base due to provincial variations in formulary timing, which can space out access milestones after federal authorization.

Across Western Europe, dermatology networks are integrating new biologics as national-level assessments advance, and the U.K. authorization in early 2025 helped catalyze earlier clinician adoption. Germany and the Nordics have experience scaling targeted biologics across immune-mediated diseases, which can help absorb prurigo nodularis starts once budget processes conclude. Southern European markets proceed more gradually due to regional decision layers and local budget constraints, though specialist centers often become early adopters. As teledermatology programs expand, clinics can reserve in-person capacity for systemic starts and complex comorbidity management, which supports stable use patterns in the prurigo nodularis therapeutics market.

Asia-Pacific is expected to post the fastest growth at a 5.24% CAGR, supported by targeted launches and scaling teledermatology that helps extend specialist reach to underserved areas. Australia's regulatory clearance in 2025 created a path for commercial rollout that can accelerate once funding decisions align with clinical practice. Japan has deep experience with biologics for inflammatory conditions, and the presence of the original developer in that market supports clinician education and patient onboarding. The Middle East & Africa and South America remain early in adoption due to capacity and reimbursement constraints, though selected private centers are building capability to manage biologic regimens. As supply chains for cold-chain delivery expand and home-based support normalizes, regional gaps in access should narrow within the prurigo nodularis therapeutics market.

1. Bayer
2. Celgene Corp. (Bristol Myers Squibb)
3. Galderma
4. GlaxoSmithKline
5. Hikma Pharmaceuticals
6. Incyte Corp.
7. Johnson & Johnson
8. Kiniksa Pharmaceuticals Ltd.
9. Maruho Co. Ltd.
10. Mayne Pharma Group Ltd.
11. Menlo Therapeutics Inc.
12. Merck
13. Novartis
14. Pfizer
15. Regeneron Pharmaceuticals
16. Sanofi
17. Takeda Pharmaceutical Co.
18. Teva Pharmaceutical Industries
19. Torii Pharmaceutical Co. Ltd.
20. Trevi Therapeutics Inc.
21. VYNE Therapeutics Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing PN diagnosis & treatment rates in high-income countries
  • 4.2.2 Regulatory tailwinds for orphan & rare-disease biologics (US & EU)
  • 4.2.3 Rapid expansion of tele-dermatology & e-pharmacy fulfilment
  • 4.2.4 IL-31 / OSM pathway breakthroughs accelerating novel MoA pipeline
  • 4.2.5 Convergence of neuro-immunology biomarkers enabling companion diagnostics
  • 4.2.6 Rise of patient-advocacy rare-disease registries speeding clinical trial enrolment
• 4.3 Market Restraints
  • 4.3.1 High biologic therapy cost & payer utilisation controls
  • 4.3.2 Limited dermatology capacity in public health systems (APAC, Africa)
  • 4.3.3 Heterogeneous disease phenotypes complicate endpoint standardisation in trials
  • 4.3.4 Supply-chain fragility for biologic fill-finish capacity
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Topical Corticosteroids
  • 5.1.2 Capsaicin Cream
  • 5.1.3 Antihistamines
  • 5.1.4 Anticonvulsants
  • 5.1.5 Antidepressants
  • 5.1.6 NK-1 Receptor Antagonists
  • 5.1.7 Biologics
  • 5.1.8 Opiate Receptor Modulators
  • 5.1.9 Others (Phototherapy, Cryotherapy, etc.)
• 5.2 By Route of Administration
  • 5.2.1 Topical
  • 5.2.2 Oral
  • 5.2.3 Subcutaneous / Intramuscular Injection
• 5.3 By End-User Setting
  • 5.3.1 Hospitals
  • 5.3.2 Specialty Dermatology Clinics
  • 5.3.3 Home-care / Self-administration
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Bayer AG
  • 6.3.2 Celgene Corp. (Bristol Myers Squibb)
  • 6.3.3 Galderma SA
  • 6.3.4 GlaxoSmithKline plc
  • 6.3.5 Hikma Pharmaceuticals plc
  • 6.3.6 Incyte Corp.
  • 6.3.7 Johnson & Johnson
  • 6.3.8 Kiniksa Pharmaceuticals Ltd.
  • 6.3.9 Maruho Co. Ltd.
  • 6.3.10 Mayne Pharma Group Ltd.
  • 6.3.11 Menlo Therapeutics Inc.
  • 6.3.12 Merck & Co. Inc.
  • 6.3.13 Novartis AG
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Regeneron Pharmaceuticals Inc.
  • 6.3.16 Sanofi SA
  • 6.3.17 Takeda Pharmaceutical Co.
  • 6.3.18 Teva Pharmaceutical Industries Ltd.
  • 6.3.19 Torii Pharmaceutical Co. Ltd.
  • 6.3.20 Trevi Therapeutics Inc.
  • 6.3.21 VYNE Therapeutics Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment